The DISCOVER Study: Evaluating the GRAIL Galleri MCED Test for Cancer Detection
The DISCOVER Study is evaluating a blood test called the GRAIL Galleri MCED test. This test looks for signs of many different types of cancer early. You might be able to join if you are at least 22 years old and have symptoms or imaging results that suggest cancer. The study aims to see how well this test can find cancer, what type of cancer it detects, and at what stage, all within 12 months of testing. This is a pilot study, meaning it's an initial evaluation, and it plans to include about 100 people.
- Study design
- This is an interventional study, meaning participants will receive a specific intervention (the GRAIL Galleri MCED test). It plans to enroll about 100 people.
- What's involved
- You would have a screening visit to check eligibility, an in-clinic visit, blood tests, and fill out questionnaires.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will follow up on diagnostic resolution and cancer type determination within 12 months after the MCED test.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
The DISCOVER Study
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Elizabeth O'Donnell, MD · PRINCIPAL_INVESTIGATOR · Dana-Farber Cancer Institute
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Multi-cancer Early Detection (MCED) Positive Cancer TypeMCED testing will be performed at enrollment, with diagnostic resolution and cancer type determination expected within 12 months.
MCED positive cancer type is defined as the type of cancer detected by the MCED test. Cancer type will be defined and recorded using ICD-O-3 codes for primary anatomic site (topography) and histology (morphology).
- Multi-cancer Early Detection (MCED) Positive Cancer IncidenceMCED testing will be performed at enrollment, with diagnostic resolution and cancer type determination expected within 12 months.
MCED positive cancer incidence is defined as the number of cancers detected by the MCED test.
- Multi-cancer Early Detection (MCED) Positive Cancer StageMCED testing will be performed at enrollment, with diagnostic resolution and cancer type determination expected within 12 months.
MCED positive cancer stage is defined as the stage of cancer detected by the MCED test.
- Multi-cancer Early Detection (MCED) Undetected Cancer TypeMCED testing will be performed at enrollment, with diagnostic resolution and cancer type determination expected within 12 months.
MCED undetected cancer type is defined as the cancer type detected by standard diagnostic methods that was not identified by the MCED test. Cancer type will be recorded using ICD-O-3 codes for both the primary anatomic site (topography) and histology (morphology).
- Multi-cancer Early Detection (MCED) Undetected Cancer IncidenceMCED testing will be performed at enrollment, with diagnostic resolution and cancer type determination expected within 12 months.
MCED undetected cancer incidence is defined as the number of cancers detected by standard diagnostic methods that was not identified by the MCED test.
- Multi-cancer Early Detection (MCED) Undetected Cancer StageMCED testing will be performed at enrollment, with diagnostic resolution and cancer type determination expected within 12 months.
MCED undetected cancer stage is defined as the stage of cancer detected by standard diagnostic methods that was not identified by the MCED test. Hodgkin lymphoma (HL) is typically staged using the Ann Arbor system; non-Hodgkin lymphoma (NHL) is staged according to the Lugano classification; multiple myeloma (MM) is staged using the International Staging System (ISS); and chronic lymphocytic leukemia (CLL) is staged according to the Rai staging system.